Although the anti-PD-L1 antibody can activate immune responses and induce apoptosis in OVCAR-3 cells, its treatment outcome falls short of that observed in unregulated ovarian cancer cells (OVCAR3). Here, CD274 is linked to ovarian carcinoma.